Skip to main content
Publications
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, Brown J, Dave V, Downey C, Shillington A, Katzenstein H, Kirker M, Hanson S, Liu F, Morris V, Bhanegaonkar A, Sonpavde G. Avelumab first-line maintenance (1LM) therapy for locally advanced/metastatic urothelial carcinoma (la/mUC): results from the realworld US PATRIOT-II study. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-a):S123.
Pluard T, Sandin R, Parikh R, Ward M, Stansfield L, Nham T, Esterberg L, Cha-Silva A, Shah B. Health care resource utilization and cost comparison among palbociclib, abemaciclib, and ribociclib in US patients with HR+/HER2− metastatic breast cancer. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S17-8. doi: 10.18553/jmcp.2023.29.10-a.s1
Hageman SHJ, Pennells L, Pajouheshnia R, Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, van der Schouw YT, Verschuren WMM, Lehmann N, Jockel KH, Di Angelantonio E, Visseren FLJ, Dorresteijn JAN. The value of additional risk factors for improving 10-year cardiovascular risk prediction in apparently healthy people. Poster presented at the European Society for Cardiology Congress 2022; August 26, 2022. Barcelona, Spain. [abstract] Eur Heart J. 2022 Oct 3; 43(Supple 2):16. doi: 10.1093/eurheartj/ehac544.2277
Hageman SHJ, Pennells L, Pajouheshnia R, Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, van der Schouw YT, Verschuren WMM, Lehmann N, Jockel KH, Di Angelantonio E, Visseren FLJ, Dorresteijn JAN. The value of additional risk factors for improving 10-year cardiovascular risk prediction in apparently healthy people. Poster presented at the ESC Congress 2022; August 26, 2022. Barcelona, Spain. [abstract] Eur Heart J. 2022 Oct 3; 43(Suppl 2). doi: 10.1093/eurheartj/ehac544.2277
Lip GYH, Diener H-C, Dubner SJ, Halperin JL, Rothman KJ, Ma C-S, Lu S, Paquette M, Riou Franca L, Zint K, Teutsch C, Huisman MV. Treatment persistence of patients with atrial fibrillation on VKA or NOAC: data from GLORIA-AF Phase III 1-year interim analysis. Poster presented at the 2019 ESC Congress; August 2019. Paris, France. [abstract] Eur Heart J. 2019 Oct 21; 40(Supplement 1):ehz745.11. doi: 10.1093/eurheartj/ehz745.1159
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Wheeler A, Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Peiper N, Learned S, Heidbreder C. Recovery from opioid use disorder post-monthly buprenorphine extended release treatment: 12-month longitudinal outcomes. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S14. doi: 10.18553/jmcp.2019.25.10-a.s1
Patterson BJ, Herring W, van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy L, Tseng H. Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: utilizing real‐world epidemiological data in a budget impact model. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, DC. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S23.